静脉序贯口服德拉沙星与万古霉素联合氨曲南治疗急性细菌性皮肤和皮肤结构感染疗效与安全性的比较:一项3期、多国、双盲、随机研究
这项多国、双盲、随机3期试验纳入850例急性细菌性皮肤和皮肤结构感染成人患者,比较德拉沙星300 mg静脉每12小时用3天后序贯口服450 mg方案与万古霉素15 mg/kg静脉联合氨曲南方案。在意向治疗分析集中,48-72小时客观缓解率德拉沙星组为83.7%,对照组为80.6%;研究者评估的随访和晚期随访成功率两组相似。德拉沙星单药治疗不劣于万古霉素联合氨曲南,且耐受性良好。
要点
- 德拉沙星静脉序贯口服方案在48-72小时客观缓解率上不劣于万古霉素联合氨曲南。
- 随访(第14±1天)研究者评估成功率德拉沙星组87.2%,对照组84.4%,晚期随访两组亦相似。
- 导致停药的治疗中出现的不良事件在万古霉素联合氨曲南组更高(1.2% vs 2.4%)。
核心结论
- 在急性细菌性皮肤和皮肤结构感染患者中,德拉沙星静脉序贯口服单药治疗在客观缓解率及随访和晚期随访的研究者评估缓解率方面均不劣于万古霉素联合氨曲南方案。
- 德拉沙星单药治疗急性细菌性皮肤和皮肤结构感染耐受性良好。
研究设计与样本
- 多中心、随机、双盲试验,纳入850例急性细菌性皮肤和皮肤结构感染成人患者。
- 德拉沙星方案为300 mg静脉每12小时用3天,序贯口服德拉沙星450 mg;对照方案为万古霉素15 mg/kg静脉联合氨曲南,疗程5-14天。
- 主要终点为48-72小时客观缓解率;次要终点包括随访(第14±1天)和晚期随访(第21-28天)基于体征和症状消退的研究者评估缓解率。
- 临床试验注册号NCT01984684。
主要发现
- 在意向治疗分析集中,48-72小时客观缓解率德拉沙星组为83.7%,万古霉素联合氨曲南组为80.6%。
- 随访时研究者评估成功率德拉沙星组为87.2%,对照组为84.4%;晚期随访分别为83.5%和82.2%。
- 随访时耐甲氧西林金黄色葡萄球菌(MRSA)清除率德拉沙星组为96.0%,万古霉素联合氨曲南组为97.0%。
- 两组治疗中出现的不良事件频率相似;导致研究药物停药的治疗中出现的不良事件在万古霉素联合氨曲南组更高(1.2% vs 2.4%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Delafloxacin is an intravenous (IV)/oral anionic fluoroquinolone with activity against gram-positive (including methicillin-resistant Staphylococcus aureus [MRSA]), gram-negative, atypical, and anaerobic organisms. It is approved in the United States for acute bacterial skin and skin structure infections (ABSSSIs) caused by designated susceptible gram-positive and gram-negative organisms, and is in development for the treatment of community-acquired bacterial pneumonia. METHODS: A multicenter, randomized, double-blind trial of 850 adults with ABSSSI compared delafloxacin 300 mg IV every 12 hours for 3 days with a switch to 450 mg oral delafloxacin, to vancomycin 15 mg/kg IV with aztreonam for 5-14 days. The primary endpoint was objective response at 48-72 hours. Investigator-assessed response based on resolution of signs and symptoms at follow-up (day 14 ± 1), and late follow-up (day 21-28) were secondary endpoints. RESULTS: In the intent-to-treat analysis set, the objective response was 83.7% in the delafloxacin arm and 80.6% in the comparator arm. Investigator-assessed success was similar at follow-up (87.2% vs 84.4%) and late follow-up (83.5% vs 82.2%). Delafloxacin was comparable to vancomycin + aztreonam in eradication of MRSA at 96.0% vs 97.0% at follow-up. Frequency of treatment-emergent adverse events between the groups was similar. Treatment-emergent adverse events leading to study drug discontinuation was higher in the vancomycin + aztreonam group (1.2% vs 2.4%). CONCLUSIONS: In ABSSSI patients, IV/oral delafloxacin monotherapy was noninferior to IV vancomycin + aztreonam combination therapy for both the objective response and the investigator-assessed response at follow-up and late follow-up. Delafloxacin was well tolerated as monotherapy in treatment of ABSSSIs. CLINICAL TRIALS REGISTRATION: NCT01984684.
引用
- O'Riordan W, McManus A, Teras J, et al. A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study. Clin Infect Dis. 2018. PMID: 29518178. doi:10.1093/cid/ciy165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。